Enanta Pharmaceuticals
US-based Enanta Pharmaceuticals develops small molecule drugs for viral infections and liver diseases.
Founded
1995US-based Enanta Pharmaceuticals develops small molecule drugs for viral infections and liver diseases.
Founded in Watertown, United States, Enanta Pharmaceuticals is a biotechnology company dedicated to the research, development, and creation of small molecule drugs targeting viral infections and liver diseases. The company's core mission is to discover and develop highly differentiated therapeutics through innovative chemistry, addressing areas of high unmet medical need. Enanta's product portfolio includes treatments for hepatitis C, respiratory syncytial virus (RSV), and non-alcoholic steatohepatitis (NASH), among others.
Enanta Pharmaceuticals boasts a team of some of the brightest minds in the pharma and biotech sectors. The company has garnered significant attention and investment from notable figures in the industry. Its key achievements include the successful development of several antiviral therapies that have made substantial impacts on patient care. Enanta's commitment to scientific excellence and bold innovation has positioned it as a leader in creating novel medicines, significantly impacting the treatment landscape for viral and liver diseases.
Companies similar to Enanta Pharmaceuticals include Anthera Pharmaceuticals, Theravance Biopharma, Aligos Therapeutics and Intercept Pharmaceuticals.
Enanta Pharmaceuticals was founded in 1995.
Enanta Pharmaceuticals' headquarters is located in Watertown, MA, US.
Enanta Pharmaceuticals' most recent funding round was for $9.2M (USD) in September 2013.
As of Sep 3, 2013, Enanta Pharmaceuticals has disclosed funding of $84.6M (USD). Undisclosed round amounts are excluded.
Enanta Pharmaceuticals has 160 employees as of Feb 6, 2024.
Intercept Pharmaceuticals
